Results 81 to 90 of about 166,279 (314)
Chanchai Traivaree,1 Napakjira Likasitthananon,2 Chalinee Monsereenusorn,1 Piya Rujkijyanont1 1Division of Hematology/Oncology, Department of Pediatrics, Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand; 2Department of Pediatrics, Lat ...
Likasitthananon N +3 more
core
Objective Studies of damage accrual in patients with systemic lupus erythematosus (SLE) show associations with disease activity measured by the SLE Disease Activity Index 2000 (SLEDAI‐2K), but these associations are imperfect. SLEDAI scores are powerfully influenced by weightings (1–8) assigned to each domain.
Kevin Zhang +8 more
wiley +1 more source
Methotrexate: an effective monotherapy for refractory generalized morphea
Eftychia Platsidaki, Vassiliki Tzanetakou, Anargyros Kouris, Panagiotis G Stavropoulos Department of Dermatology and Venereology, Andreas Syggros Hospital, University of Athens, Athens, Greece Introduction: Morphea is an inflammatory skin ...
Tzanetakou V +7 more
core +1 more source
Consumed by Abdominal Distention
Arthritis Care &Research, EarlyView.
Abimbola Fadairo‐Azinge +3 more
wiley +1 more source
Objective This study aimed to describe real‐world trends in preconception and prenatal use of antirheumatic drugs among pregnant individuals with rheumatic diseases in Ontario, Canada. Methods We conducted a time‐series analysis using repeated cross‐sectional data to examine annual patterns of disease‐modifying antirheumatic drug (DMARD) use among ...
Shenthuraan Tharmarajah +6 more
wiley +1 more source
Glucarpidase to combat toxic levels of methotrexate in patients
Jacalyn M GreenDepartment of Biochemistry, Midwestern University, IL, USAAbstract: In January 2012, glucarpidase (Voraxaze®) received approval from the US Food and Drug Administration for intravenous treatment of toxic plasma methotrexate ...
Green JM
core
Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate
About 20% of patients with a history of atherosclerotic cardiovascular disease will experience further cardiovascular events despite maximal pharmacological treatment with cardioprotective drugs.
Tommasi, Sara +20 more
core +1 more source
Introduction It is unknown if a temporary break in long-term immune-suppressive treatment after vaccination against COVID-19 improves vaccine response. The objective of this study was to evaluate if a 2-week interruption in low-dose weekly methotrexate ...
Julier, P. +40 more
core +1 more source
Objective This study aims to investigate lifestyle‐related factors in patients with psoriatic arthritis (PsA) and their association with disease activity measurements. Methods This multicenter cohort included 938 patients who were newly diagnosed with PsA between 2013 and 2023.
Batoul Hojeij +11 more
wiley +1 more source
Methotrexate-induced cutaneous ulceration in patients with erythrodermic mycosis fungoides
Debra L Breneman1, Timothy J Storer2, John C Breneman3, Diya F Mutasim41University of Cincinnati Medical Center, Dept of Dermatology, Cincinnati, Ohio, USA; 2Smith Clinic, Delaware, Ohio, USA; 3University of Cincinnati Medical Center, Dept of Radiology ...
Diya F Mutasim +3 more
core

